Condition: Macular Edema Secondary to Inflammation · Sponsor: Kodiak Sciences Inc
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants with Macular Edema Secondary to Inflammation (MESI)
This description comes directly from the study's public registry record.
Kodiak Sciences Inc · (650) 281-0850 · ClinicalTrials@kodiak.com
Always discuss trial participation with your own doctor first.
| AZ Retina & Vitreous Consultants | Phoenix, Arizona, United States | Recruiting |
| Research Network Arizona | Scottsdale, Arizona, United States | Recruiting |
| California Retina Consultants (Bakersfield) | Bakersfield, California, United States | Recruiting |
| Global Research Management, Inc. | Glendale, California, United States | Recruiting |
| UCSD/Jacobs Retina Center | La Jolla, California, United States | Recruiting |
| UCLA Stein Eye Institute | Los Angeles, California, United States | Recruiting |
| California Retina Consultants (Oxnard) | Oxnard, California, United States | Recruiting |
| Stanford Byers Eye Institute | Palo Alto, California, United States | Not Yet Recruiting |
| California Eye Specialists Medical Group, Inc. | Pasadena, California, United States | Recruiting |
| California Eye Specialists Medical Group, Inc. | Redlands, California, United States | Recruiting |
| Retina Consultants of Southern California | Redlands, California, United States | Recruiting |
| Retinal Consultants Medical Group Inc | Sacramento, California, United States | Recruiting |
+ 44 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06990399